FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma By Ogkologos - July 22, 2026 140 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab November 15, 2023 Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... September 18, 2019 Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in... December 10, 2020 Load more HOT NEWS Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance... Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... EMA Recommends Extension of Indications for Crizotinib How I Navigated Being a Young Mom During Cancer: A Survivor’s...
